Inventor · disambiguated record
Michael Briskin
Also filed as: BRISKIN MICHAEL · BRISKIN MICHAEL J · BRISKIN MICHAEL JOSEPH
8 granted patents·12 pending applications·142 citations·filing 1995–2023
87Inventor score
Files withMILLENNIUM PHARM INC10PHENOMIC AI3STEWART EDWARD J3BRISKIN MICHAEL J2OBSIDIAN THERAPEUTICS INC2
Top patents by PatentIndex Score
20 records- 0184US7038018B2Antibodies and ligands for “Bonzo” chemokine receptorMILLENNIUM PHARM INC·Filed 2001·Granted May 2, 2006·22 cites·60 claims
- 0284US6423514B1Mammalian hyaluronan synthases, nucleic acids and uses thereofMILLENNIUM PHARM INC·Filed 1996·Granted Jul 23, 2002·60 cites·14 claims
- 0381US8277808B2Mucosal vascular addressins and uses thereofBRISKIN MICHAEL J·Filed 2007·Granted Oct 2, 2012·7 cites·14 claims
- 0466US6514497B1Inhibition of LERK-2-mediated cell adhesionMILLENNIUM PHARM INC·Filed 1998·Granted Feb 4, 2003·29 cites·8 claims
- 0565US7208152B2Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereofMILLENNIUM PHARM INC·Filed 2002·Granted Apr 24, 2007·1 cites·68 claims
- 0663US2025215070A1Anti-cthrc1 fusion proteins and methods of using the samePHENOMIC AI·Filed 2023·Application pending·0 cites
- 0762US2025213710A1Anti-collagen triple helix repeat containing 1 (cthrc1) antibodies and methods of using the samePHENOMIC AI·Filed 2023·Application pending·0 cites
- 0861US7803904B2Mucosal vascular addressing and uses thereofMILLENNIUM PHARM INC·Filed 1996·Granted Sep 28, 2010·13 cites·60 claims
- 0956US2013022607A1Mucosal vascular addressins and uses thereofMILLENNIUM PHARM INC·Filed 2012·Application pending·0 cites
- 1052US2006057135A1Mucosal vascular addressins and uses thereofBRISKIN MICHAEL J·Filed 2005·Application pending·0 cites
- 1150US2002151026A1Mammalian hyaluronan synthases, nucleic acids and uses thereofMILLENNIUM PHARM INC·Filed 2001·Application pending·0 cites
- 1250US2003082182A1Novel mucosal vascular addressinsMILLENNIUM PHARM INC·Filed 2001·Application pending·0 cites
- 1349US2022175781A1Cd40l compositions and methods for tunable regulationOBSIDIAN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1448US2010028297A1Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosisSTEWART EDWARD J·Filed 2007·Application pending·0 cites
- 1547US2025059267A1Combination therapy for treatment of tumors comprising cancer-associated fibroblastsPHENOMIC AI·Filed 2022·Application pending·0 cites
- 1646US2023092895A1Tandem cd19 car-based compositions and methods for immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1744US6319675B1Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptorMILLENNIUM PHARM INC·Filed 1999·Granted Nov 20, 2001·10 cites·58 claims
- 1840US2010150915A1Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonistSTEWART EDWARD J·Filed 2008·Application pending·0 cites
- 1939US2012087934A1Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosisSTEWART EDWARD J·Filed 2011·Application pending·0 cites
- 2030US7750137B2Mucosal vascular addressinsMILLENNIUM PHARM INC·Filed 1995·Granted Jul 6, 2010·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Michael Briskin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →